As of November this year, based on Medpace Holdings's latest financial report, the company's current EPS (TTM) is $14.66. Medpace Holdings's earnings per share in 2024 came in at $13.06, marking an increase from $9.2 in 2023. Medpace Holdings's EPS for the quarterly period ending on Sep 30, 2025 was $3.95.
The yearly EPS in 2024 was $13.06, an increase of 42% compared to $9.2 recorded in 2023. The quarterly EPS for the period ending Sep 30, 2025, was $3.95, marking a 27% increase compared to the same quarter last year. MEDP's TTM EPS is $14.66 as of September 2025. Medpace Holdings's EPS for 2023 was $9.2, a 21.5% rise from 2022.
Medpace Holdings has recorded a growth in earnings per share of 27% over the past 12 months (YoY, quarterly). For the last three years, MEDP had an average yearly EPS growth of 37.2%. Medpace Holdings had an average annual EPS growth of 36.2% over the last five years.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| MEDP Medpace Holdings Inc | 40.53 | 42% | 37.2% | 36.2% |
| OLMA Olema Pharmaceuticals Inc | N/A | -2.8% | N/A | N/A |
| OMER Omeros Corp | N/A | -43.6% | N/A | N/A |
| VIVS VivoSim Labs Inc. | N/A | 91.2% | N/A | N/A |
| ORIC Oric Pharmaceuticals Inc | N/A | 6.6% | N/A | N/A |
| ORMP Oramed Pharmaceuticals Inc | N/A | -442.9% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.